De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

McKesson Toekomstige groei

Future criteriumcontroles 2/6

McKesson zal naar verwachting groeien in winst en omzet met respectievelijk 10% en 8.2% per jaar. De winst per aandeel zal naar verwachting groeien met 13.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 247.5% zijn.

Belangrijke informatie

9.8%

Groei van de winst

13.4%

Groei van de winst per aandeel

Healthcare winstgroei	19.3%
Inkomstengroei	8.1%
Toekomstig rendement op eigen vermogen	247.5%
Dekking van analisten	Good
Laatst bijgewerkt	03 Oct 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M

Feb 01

McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

Jan 12

5 Reasons Why I Am Considering Adding McKesson To My Portfolio

Dec 27

McKesson Corporation: Still Trading Below Intrinsic Value

Dec 13

Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus

Oct 08

McKesson extends distribution partnership with CVS Health

Sep 29

An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

Sep 19

McKesson to acquire Rx Savings Solutions in $875M deal

Sep 19

Winst- en omzetgroeiprognoses

NYSE:MCK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	411,198	4,385	5,719	6,473	11
3/31/2026	382,635	4,038	4,885	5,892	15
3/31/2025	351,831	3,750	5,005	5,746	15
6/30/2024	313,751	2,959	3,256	3,986	N/A
3/31/2024	308,951	3,002	3,627	4,314	N/A
12/31/2023	301,506	2,998	2,892	3,492	N/A
9/30/2023	291,098	3,487	4,306	4,906	N/A
6/30/2023	284,040	3,755	4,466	5,048	N/A
3/31/2023	276,711	3,563	4,601	5,159	N/A
12/31/2022	273,903	3,146	4,190	4,721	N/A
9/30/2022	272,027	2,061	3,952	4,430	N/A
6/30/2022	268,446	1,396	4,639	5,115	N/A
3/31/2022	263,966	1,119	3,899	4,434	N/A
12/31/2021	257,006	1,415	4,323	4,917	N/A
9/30/2021	250,991	-4,804	4,098	4,753	N/A
6/30/2021	245,223	-4,494	3,299	3,982	N/A
3/31/2021	238,228	-4,538	3,901	4,542	N/A
12/31/2020	237,621	-4,189	5,231	5,826	N/A
9/30/2020	234,194	2,228	3,905	4,492	N/A
6/30/2020	231,002	922	2,851	3,363	N/A
3/31/2020	231,051	906	3,868	4,374	N/A
12/31/2019	224,945	-905	3,125	3,615	N/A
9/30/2019	221,981	-626	3,066	3,559	N/A
6/30/2019	217,440	601	4,523	5,046	N/A
3/31/2019	214,319	33	3,479	4,036	N/A
12/31/2018	213,518	-319	2,572	3,165	N/A
9/30/2018	210,927	113	2,751	3,324	N/A
6/30/2018	209,913	-384	1,936	2,543	N/A
3/31/2018	208,357	62	N/A	4,345	N/A
12/31/2017	205,442	4,805	N/A	2,756	N/A
9/30/2017	201,955	4,539	N/A	3,155	N/A
6/30/2017	199,851	4,846	N/A	3,626	N/A
3/31/2017	198,533	5,194	N/A	4,744	N/A
12/31/2016	196,498	2,051	N/A	6,415	N/A
9/30/2016	194,267	2,044	N/A	5,349	N/A
6/30/2016	193,071	2,359	N/A	5,077	N/A
3/31/2016	190,884	2,290	N/A	3,672	N/A
12/31/2015	189,131	2,237	N/A	2,449	N/A
9/30/2015	187,716	2,090	N/A	4,198	N/A
6/30/2015	183,115	1,950	N/A	3,384	N/A
3/31/2015	179,045	1,775	N/A	3,112	N/A
12/31/2014	171,952	1,780	N/A	3,893	N/A
9/30/2014	159,804	1,462	N/A	2,488	N/A
6/30/2014	148,629	1,402	N/A	2,602	N/A
3/31/2014	137,392	1,419	N/A	3,136	N/A
12/31/2013	130,076	1,278	N/A	2,679	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MCK ( 10% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van MCK ( 10% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.2% per jaar).

Hoge groeiwinsten: De winst van MCK zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van MCK ( 8.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van MCK ( 8.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MCK zal naar verwachting over 3 jaar zeer hoog zijn ( 247.5 %).

McKesson Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies

McKesson Corporation to Report Q2, 2025 Results on Nov 06, 2024

McKesson: The Correction Is Not Over

CEO & Director notifies of intention to sell stock

Upcoming dividend of US$0.71 per share

McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO & Director notifies of intention to sell stock

Fourth quarter dividend increased to US$0.71

McKesson Corporation Declares Regular Dividend on Common Stock, Payable on October 1, 2024

CEO & Director notifies of intention to sell stock

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

McKesson Corporation to Report Q1, 2025 Results on Aug 07, 2024

McKesson Corporation, Annual General Meeting, Jul 31, 2024

Mckesson Corporation Elects Deborah Dunsire as New Director

Upcoming dividend of US$0.62 per share

Executive VP & CFO notifies of intention to sell stock

With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

Full year 2024 earnings: EPS exceeds analyst expectations

Third quarter dividend of US$0.62 announced

McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024

McKesson Corporation to Report Q4, 2024 Results on May 07, 2024

CEO & Director notifies of intention to sell stock

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Upcoming dividend of US$0.62 per share

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter dividend of US$0.62 announced

High number of new directors

Mckesson Corporation Declares Quarterly Dividend, Payable on April 1, 2024

Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

McKesson: Why The Company Is Too Richly Valued

McKesson Corporation Reportedly Seeks Buyers for Canada's Rexall Pharmacy

McKesson Corporation (NYSE:MCK) acquired Compile, Inc.

Mckesson Corporation Elects Kevin Ozan as New Director

CEO & Director notifies of intention to sell stock

McKesson Corporation to Report Q3, 2024 Results on Feb 07, 2024

McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas

Upcoming dividend of US$0.62 per share at 0.5% yield

If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

CEO & Director notifies of intention to sell stock

McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

McKesson Corporation Announces Management Changes

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2024

CEO & Director notifies of intention to sell stock

McKesson Corporation to Report Q2, 2024 Results on Nov 01, 2023

McKesson: Still Trading For A Huge Discount

Upcoming dividend of US$0.62 per share at 0.6% yield

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

McKesson Corporation Raises Quarterly Dividend, Payable on October 2, 2023

CEO & Director notifies of intention to sell stock

McKesson Corporation to Report Q1, 2024 Results on Aug 02, 2023

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

McKesson Unveils New Private Brand of Over-the-Counter Pharmacy Products

CEO & Director notifies of intention to sell stock

McKesson Corporation, Annual General Meeting, Jul 21, 2023

McKesson Corporation, Annual General Meeting, Jul 21, 2023

Executive VP exercised options and sold US$424k worth of stock

Upcoming dividend of US$0.54 per share at 0.5% yield

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

CEO & Director notifies of intention to sell stock

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Senior VP exercised options and sold US$88k worth of stock

Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

Upcoming dividend of US$0.54 per share at 0.6% yield

McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth